论文部分内容阅读
用双重抗血小板治疗的急性冠状动脉综合征(acute coronary syndromes,ACS)患者在初次就诊测量的生长分化因子15(growth differentiation factor-15,GDF-15)与大出血相关。然而,后续测量能否提供额外的信息未知。该项研究的目的是调查在ACS后1个月测量的GDF-15水平能否比基线测定时更进一步预测大出血的风险。方法:纳入血小板抑制与患者预
Patients with acute coronary syndromes (ACS) treated with dual antiplatelet therapy are associated with major bleeding when measured on their first visit with growth differentiation factor-15 (GDF-15). However, the follow-up measurement can provide additional information unknown. The purpose of this study was to investigate whether the level of GDF-15 measured at 1 month after ACS can predict the risk of major bleeding further than at baseline. Methods: Inclusion of platelet inhibition and patient preconditioning